1 / 14

National R &D Oncology Consortium PI: J. T í már MD PhD

National R &D Oncology Consortium PI: J. T í már MD PhD. National Institute of Oncology Rath Gy 7-9, Budapest,H-1122 Hungary. Cancer morbidity and mortality’1999, Hungary. female male. MT (15000) MB MT (19000) MB. National Institute of Neurosurgery

matsu
Download Presentation

National R &D Oncology Consortium PI: J. T í már MD PhD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. National R&D Oncology ConsortiumPI: J. Tímár MD PhD National Institute of Oncology Rath Gy 7-9, Budapest,H-1122 Hungary

  2. Cancer morbidity and mortality’1999, Hungary female male MT (15000) MB MT (19000) MB

  3. National Institute of Neurosurgery National Institute of Pulmonology National Institute of Epidemiology Department of Pediatrics, Debrecen U. Department of Immunology and Biotechnology, Pécs University 1st Institute of Pathology & Experimental Cancer Research, Semmelweis University, Budapest Department of Oncotherapy, Szeged University Institute of Biotechnology, Bay Z. Fundation, Szeged National Institute of Rabiobiology AstraZeneca Hungary Aventis Pharma Hungary Béres Co. Hungary Byk-Gulden Janssen-Cilag, Johnson and Johnson Pannonpark Ltd Pharmacia Hungary Bristol-Myers-Squibb Hungary National Oncology R&D Conzorcium (Hungary) National institute of Oncology

  4. Cancer types to be investigated • Breast ca. • Lung ca. • Colorectal ca. • Head and neck ca. • Cervical ca. • Ovarian ca. • Malignant melanoma • Soft tissue sarcoma • Pediatric cancers: acute leukemia • neuroblastoma • nephroblastoma • glioblastoma

  5. Methodology • Laser-microdissection • Global genome analysis • DNA microarry design, production • real time quantitatív PCR • antibody design and production • protein-chip technology • in situ hibridization

  6. Laser-microdissection DNS RNS protein

  7. Mutational analysis Breast cancer T V N GAPDH MAM HER-2 TOPT II

  8. Quantitative PCR 10x 20x 40x 80x 160x 2 kópia 1 kópia

  9. Confocal Laser scanning microscopy

  10. Screening and prevention • Susceptibility: • drug metabolizing enzim-polymorphism • Familiar breast, ovarian and colorectal cancer screening • Genetical predisposition • Neuroblastoma

  11. Diagnostics • Molecular diagnostics • soft tissue tumors • Molecular staging • colorectal-, breast-, head and neck, ALL, NBL • Prognostic pathology • colorectal-, breast-, lung-,head and neck, melanoma • Sensitivity to therapy: • drug metabolizing enzime polymorphism • drug-target identification

  12. Novel therapeutic modalities • Breast cancer: • Chemoprevention, New taxanes • combination of taxanes and Herceptin • Melanoma: • Fragmin (lmw heparin) • Cervical ca., rectal ca: • rhErythropoetin • Glioblastoma: • gene therapy

  13. Biotech products • New method for blood detection in the stool • WT1 oncogene probes, antibodies • “Designer” oligo-chips for • differential diagnosis of soft tissue tumors • drug targets in breast-, head and neck cancers • Gene-map of tumor progression • drig metabolizing enzime polymorphism • Design of protein chips for tumor progression • cytokine-producing vestor systems • geneticaly engenered human glioblastoma cell lines

  14. 9.Gene therapy of brain tumors 2.Screening and prognosis of colorectal cancer 1.Mol - epidemiol Béres Rt. OTFH ANTSZ SZBK BYK BayZA OSSKI SZBK 8.Molecular pharmacology Pharmacia SE-1PKRKI SZBK OIsTI 3.Mol diag nos tics OKTPI SZE-OTK SZBK National Institute of Oncology PTE-IBI SZBK J. Tímár PI Pharmacia Jansen-Cilag 7.Tumor Progression SZBK AstraZeneca Aventis PharmavitBMS DE-GYK SZBK 4. Mol.diag. therapy of breast cc SZBK BYK 5.Mol.epidemiol. Diag. of head and neck cancer 6. Pediatric oncology

More Related